Literature DB >> 28194671

Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.

Cindy X Cai1,2, Hema Buddha3,4, Shobha Castelino-Prabhu5, Zhiwei Zhang6, Robert S Britton4, Bruce R Bacon4, Brent A Neuschwander-Tetri4.   

Abstract

BACKGROUND AND AIMS: Hyperinsulinemia and insulin resistance are hallmark features of nonalcoholic fatty liver disease and steatohepatitis (NASH). It remains unclear whether and how insulin contributes to the development of fibrosis in NASH. In this study, we explored insulin signaling in the regulation of hepatic stellate cell (HSC) activation and the progression of NASH-fibrosis.
METHODS: Phosphorylation of Akt and p70S6K were examined in primary HSC and in a rat model of NASH-fibrosis induced by high-fat and high-cholesterol diet for 24 weeks. HSC activation was analyzed for the changes in cell morphology, intracellular lipid droplets, expression of α-SMA and cell proliferation. The serum markers and histology for NASH-fibrosis were also characterized in animals.
RESULTS: Insulin enhanced the expression of smooth muscle actin-α in quiescent but not in activated HSC in culture. Insulin-mediated activation of the PI3K/Akt-p70S6K pathway was involved in the regulation of profibrogenic effects of insulin. Although insulin did not stimulate HSC proliferation directly, the insulin-PI3K/Akt-p70S6K pathway was necessary for serum-enhanced cell proliferation during initial HSC activation. In a rat model of NASH-fibrosis induced by high-fat and high-cholesterol diet, hyperinsulinemia is associated with the activation of p70S6K and enhanced fibrosis.
CONCLUSION: The insulin-PI3K/Akt-p70S6K pathway plays an important role in the early activation of HSC. The profibrogenic effect of insulin is dependent on the activation stage of HSC. Dysregulation of the insulin pathway likely correlates with the development of fibrosis in NASH, suggesting a potentially novel antifibrotic target of inhibiting insulin signaling in HSC.

Entities:  

Keywords:  Hepatic stellate cells; High-fat and high-cholesterol diet; Insulin signaling pathway; Liver fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2017        PMID: 28194671     DOI: 10.1007/s10620-017-4470-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  58 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 2.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

Review 3.  Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

4.  Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

Authors:  Andrea Tura; Giovanni Pacini; Alexandra Kautzky-Willer; Bernhard Ludvik; Rudolf Prager; Karl Thomaseth
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-04-01       Impact factor: 4.310

5.  Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.

Authors:  Erwin Biecker; Andrea De Gottardi; Markus Neef; Matthias Unternährer; Vreni Schneider; Monika Ledermann; Hans Sägesser; Sidney Shaw; Jürg Reichen
Journal:  J Pharmacol Exp Ther       Date:  2005-03-15       Impact factor: 4.030

6.  The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation.

Authors:  Erwin Gäbele; Shimon Reif; Shigeki Tsukada; Ramon Bataller; Yutaka Yata; Terry Morris; Laura W Schrum; David A Brenner; Richard A Rippe
Journal:  J Biol Chem       Date:  2005-01-26       Impact factor: 5.157

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.

Authors:  Jia Xiao; Chi Tat Ho; Emily C Liong; Amin A Nanji; Tung Ming Leung; Thomas Yue Huen Lau; Man Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2013-03-21       Impact factor: 5.614

Review 9.  Promising Therapy Candidates for Liver Fibrosis.

Authors:  Ping Wang; Yukinori Koyama; Xiao Liu; Jun Xu; Hsiao-Yen Ma; Shuang Liang; In H Kim; David A Brenner; Tatiana Kisseleva
Journal:  Front Physiol       Date:  2016-02-16       Impact factor: 4.566

10.  Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.

Authors:  Wei Wang; Caiyan Zhao; Junying Zhou; Zhen Zhen; Yadong Wang; Chuan Shen
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  16 in total

1.  Pharmacological Mechanism of Ganlu Powder in the Treatment of NASH Based on Network Pharmacology and Molecular Docking.

Authors:  Rui Gao; Xiaobo Zhang; Zhen Zhou; Jiayi Sun; Xuehua Tang; Jialiang Li; Xin Zhou; Tao Shen
Journal:  Dis Markers       Date:  2022-06-29       Impact factor: 3.464

2.  Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.

Authors:  Justin F Creeden; Zachary A Kipp; Mei Xu; Robert M Flight; Hunter N B Moseley; Genesee J Martinez; Wang-Hsin Lee; Khaled Alganem; Ali S Imami; Megan R McMullen; Sanjoy Roychowdhury; Atta M Nawabi; Jennifer A Hipp; Samir Softic; Steven A Weinman; Robert McCullumsmith; Laura E Nagy; Terry D Hinds
Journal:  Hepatology       Date:  2022-04-08       Impact factor: 17.298

3.  Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway.

Authors:  Pradeep Kumar; Reben Raeman; Daniel M Chopyk; Tekla Smith; Kiran Verma; Yunshan Liu; Frank A Anania
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-08       Impact factor: 5.187

4.  Expression of neuropeptide Y is increased in an activated human HSC cell line.

Authors:  Wufei Dai; Yang Liu; Yali Zhang; Yufeng Sun; Changjiang Sun; Yu Zhang; Xiufang Lv
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

5.  Nrf2 protects stellate cells from Smad-dependent cell activation.

Authors:  Vincenzo Prestigiacomo; Laura Suter-Dick
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

6.  Inhibitory effect of blue honeysuckle extract on high-fat-diet-induced fatty liver in mice.

Authors:  Ming Liu; Jijun Tan; Ziyu He; Xi He; De-Xing Hou; Jianhua He; Shusong Wu
Journal:  Anim Nutr       Date:  2018-06-27

7.  Sheng-Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats.

Authors:  Juan Li; Lv Zhu; Yu-Mei Zhang; Huan Chen; Yi-Fan Miao; Hong-Xin Kang; Hong-Yu Ren; Mei-Hua Wan; Dan Long; Wen-Fu Tang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-04       Impact factor: 2.629

8.  Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study.

Authors:  Chien-Hsieh Chiang; Chia-Sheng Kuo; Wan-Wan Lin; Jun-Han Su; Jin-De Chen; Kuo-Chin Huang
Journal:  Int J Environ Res Public Health       Date:  2019-06-13       Impact factor: 3.390

9.  Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model.

Authors:  Katsuyuki Tokinoya; Nanami Sekine; Kai Aoki; Seiko Ono; Tomoaki Kuji; Takehito Sugasawa; Yasuko Yoshida; Kazuhiro Takekoshi
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

10.  Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture.

Authors:  Susumu Hamada-Tsutsumi; Masaya Onishi; Kentaro Matsuura; Masanori Isogawa; Keigo Kawashima; Yusuke Sato; Yasuhito Tanaka
Journal:  Int J Mol Sci       Date:  2020-10-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.